SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys quarterly earnings beat and raised revenue outlook, driven by strong demand for Mounjaro and Zepbound, are fueling the rally and record-high discussion. Traders are broadly bullish on GLP-1 growth, while some flag the rich valuation, lower profit guidance tied to acquisition-related charges, and weaker-than-expected Foundayo sales.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price jump and fresh highs. Traders are largely celebrating the results and breakout, while debating whether the rally can hold or will pull back.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and slightly raised its outlook, but shares sold off to a new 52-week low as traders questioned the modest growth, the contribution of an Israeli R&D grant to profitability, and the companys ability to win advanced-driving programs amid competition. The reaction is split between bearish short sellers and investors who view the cash position and autonomous-driving opportunities as support for a recovery.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high is drawing attention ahead of its expected Q3 report, with traders focused on BRIUMVIs sales momentum and guidance, plus the coming subcutaneous data. Buyout and short-squeeze theories are adding to bullish sentiment, though those remain speculation and some traders caution that strong results may already be priced in.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 results for Amgens IMDELLTRAImfinzi combination in extensive-stage small-cell lung cancer have reinforced the pipeline story as shares reach fresh highs. Traders are weighing the potential commercial impact against upcoming earnings, with some viewing put activity as a hedge rather than a bearish bet.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Traders are focused on the anticipated completion of Compass Pathways rolling NDA submission for COMP360, its investigational psilocybin therapy for treatment-resistant depression, and the potential for an expedited FDA review. Many expect the filing to be a catalyst, while others are frustrated by the delay and cautious about the share-price weakness and uncertainty around approval.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of layoffs affecting roughly 550 employees in India, with additional cuts reported in the Philippines, have raised concern that a client project is being scaled back and could signal lost revenue. Traders are split between fearing a major customer or contract loss and viewing the cuts as an efficiency move or overreaction, with many looking to the upcoming earnings report for clarification.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reached its 80th overall-survival event, triggering database lock and final analysis ahead of topline results expected in Q4. Traders are divided: bullish posts interpret the trials long duration as a possible sign of benefit from GPS, while skeptics stress that the milestone reveals no treatment-arm results and point to unresolved trial-design questions and the share-price decline.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

A Northland upgrade citing C3 Codes potential to speed development of agentic AI applications is a prominent catalyst in the discussion. Traders are split on whether the renewed optimism and call activity can overcome concerns about declining revenue and execution, while some speculate about a short squeeze.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp selloff in gold has pushed GLD to a 52-week low, with traders citing expectations for a more hawkish Fed and possible forced liquidation as pressure on the metal. The move has prompted debate over golds safe-haven role: bears see more downside, while some investors are treating the drop as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MakeMyTrip (MMYT) Q2 2027 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

MakeMyTrip Q2 2027 Earnings Call Transcript

MakeMyTrip (NASDAQ:MMYT) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...

MakeMyTrip Q2 27 Earnings Conference Call At 7:30 AM ET

(RTTNews) - MakeMyTrip Ltd. (MMYT) will host a conference call at 7:30 AM ET on October 26, 2026, to discuss Q2 27 earnings results...

MakeMyTrip Limited to report Fiscal 2027 Second Quarter Financial & Operating Results on October 26, 2026

MakeMyTrip Limited (Nasdaq: MMYT) plans to report its fiscal 2027 second quarter financial and operating results before markets open on Monday, October 26, 2026. The company will post the release on its Investor Relations website at https://investors.makemytrip.com/ and will not distribute over...

Is It Worth Investing in MakeMyTrip (MMYT) Based on Wall Street's Bullish Views?

Based on the average brokerage recommendation (ABR), MakeMyTrip (MMYT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

MakeMyTrip Q1 2027 Earnings Call Transcript

On Monday, MakeMyTrip (NASDAQ:MMYT) discussed first-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financial dataread more...

Is MakeMyTrip (MMYT) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in MakeMyTrip (MMYT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Industry Outlook GoDaddy, Vipshop, MakeMyTrip and QuinStreet 

GoDaddy, Vipshop, MakeMyTrip and QuinStreet have been highlighted in this Industry Outlook article.


4 Internet Delivery Services Stocks in Focus From a Flourishing Industry

The Zacks Internet - Delivery Services industry participants like GDDY, VIPS, MMYT and QNST are likely to benefit from increasing smartphone and Internet penetration.

Brokers Suggest Investing in MakeMyTrip (MMYT): Read This Before Placing a Bet

MakeMyTrip Ltd. engages in the provision of travel services. It offers air ticketing, hotels and packages, rail tickets, bus tickets, car hire, experiences and ancillary travel requirements such as foreign currency exchange services, visa processing, facilitating access to travel, and other insurance products. The company was founded by Deep Kalra and Rajesh Magow on April 28, 2000 and is headquartered in Gurgaon, India.

MakeMyTrip Ltd

Why Did MakeMyTrip Stock Fall Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Citi cut MakeMyTrip’s price target to $96 from $108, while maintaining a ‘Buy’ rating on the shares after its earnings results.&nbsp;</li><li>Morgan Stanley lowered its price target on the company to $106 from $113 while maintaining an ‘Overweight’ rating on the shares.&nbsp;</li><li>The company missed revenue estimates, reporting quarterly revenue of $295.7 billion, compared to analyst expectations of $310 billion, as per Fiscal.ai data.</li></ul><p>Shares of online travel company MakeMyTrip Ltd. (MMYT) fell over 12% on Wednesday after the company received target price cuts from Morgan Stanley and Citi following its third-quarter (Q3) 2026 results.</p><p>Citi cut MakeMyTrip’s price target to $96 from $108, while maintaining a ‘Buy’ rating on the shares after its earnings results.</p><p>Meanwhile, Morgan Stanley lowered its price target on MakeMyTrip to $106 from $113 while maintaining an ‘Overweight’ rating on the shares.</p><h2 class="st-heading-2">Earnings Results</h2><p>The company missed revenue estimates, reporting quarterly revenue of $295.7 billion, compared to analyst expectations of $310 billion, as per Fiscal.ai data.</p><p>However, MakeMyTrip beat analyst expectations on earnings per share, reporting $0.07 EPS for the quarter, versus an expectation of $0.01.</p><p>For the quarter, the company’s adjusted net profit grew to $51.4 million versus $44.9 million in the same period last year, an improvement of $6.5 million. The company also reported a 11.8% increase in gross bookings. The company’s profit for the quarter decreased almost 73% year-on-year to $7.3 million in Q3 26, compared to $27.1 million in Q3 25.</p><h2 class="st-heading-2">Street Consensus</h2><p>Morgan Stanley said it lowered its price target on MakeMyTrip after the company's latest earnings report. The analyst said it lowered its estimates to moderate the expected pace of margin expansion for FY27 and FY28, according to TheFly.</p><p>Meanwhile, Citi said that it views MakeMyTrip’s growth as solid amid "challenging circumstances," according to TheFly. However, the analyst lowered its estimates after the company’s earnings, factoring in more modest margin assumptions.</p><p>Citi, however, said that it views MakeMyTrip's valuation as attractive at current share levels.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MMYT">MMYT shares</a> remained in the ‘neutral’ territory over the past 24 hours amid ‘high’ message volumes.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_22_at_3_19_19_AM_png_0d39fc48a4.webp" alt="On Stocktwits, retail sentiment around MMYT shares remained in the ‘neutral’ territory over the past 24 hours amid ‘high’ message volumes." width="1274" height="153"></figure><p>Shares of MMYT lost over 34% in the past year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

People travel through Hartsfield-Jackson Atlanta International Airport on November 7, 2025 in Atlanta, Georgia. (Photo by Megan Varner/Getty Images)

MakeMyTrip Ltd. received target price cuts from Morgan Stanley and Citi following its third-quarter results that were below market expectations. 

Amplify Travel Tech ETF

Exchange Traded Concepts Trust - ETCT EMQQ The Emerging Markets Internet and Ecommerce ETF

SPDR Portfolio Emerging Markets ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MMYT News